Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 8c; Cash and Cash Equivalents of $240.3M
November 4, 2021 7:21 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q3 EPS of ($0.57), $0.08 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $2.25 million.
For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.
... More